Independent of ERCC1 assessment, we previously confirmed the negative prognostic impact of CTCs before surgery and after chemotherapy, as detected by the AdnaTest Ovarian Cancer [21, 29]. The gene discussed is ERCC1; the disease is ovarian cancer.